Intermediate end point cardiovascular clinical trials: an excellent idea based on an obsolete paradigm

References

• Moghadasian MH. Experimental atherosclerosis: a historical review. Life Sci 2002;70:855-65
   PubMed Web of Science ®Google Scholar
• Keys A. Human atherosclerosis and the diet. Circulation 1952;5:115-18
   PubMed Web of Science ®Google Scholar
• Fuster JJ, Castillo AL, Zaragoza C, et al. Animal models of atherosclerosis. Prog Mol Biol Transl Sci 2012;105:1-23
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy in coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a results of intensive lipid- lowering therapy in men with high levels of apolipoprotein Br N Engl J Med. 1990;323:1289-98
   Google Scholar
• Crouse JR 3rd, Raichlen JS, Riley WA, et al. METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344-53
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358(14):1431-43
   PubMed Web of Science ®Google Scholar
• Bots ML, Visseren FL, Evans GW, et al. RADIANCE 2 Investigators. Torcetrapib and carotid intima-media thickness in mixed dyslipidemia (RADIANCE 2 study): a randomized, double-blind trial. Lancet 2007;370(9582):153-60
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, van Leuven SI, Burgess L, et al. RADIANCE 1 Investigators. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30
   PubMed Web of Science ®Google Scholar
• Meuwese MC, de Groot E, Duivenvoorden R, et al. CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009;301:1131-9
   PubMed Web of Science ®Google Scholar
• Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-6
   PubMed Web of Science ®Google Scholar
• Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E: the St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol 2005;46:166-72
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Taddei S, Kaski JC, et al. dal-VESSEL Investigators. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012;33(7):857-65
   PubMed Web of Science ®Google Scholar
• Kelemen M, Vaidya D, Waters DD, et al. Hormone therapy and antioxidant vitamins do not improve endothelial vasodilator function in postmenopausal women with established coronary artery disease: a substudy of the Women's Angiographic Vitamin and Estrogen (WAVE) trial. Atherosclerosis 2005;179:193-200
   PubMed Web of Science ®Google Scholar
• Wierzbicki AS. Muddy waters: more stormy SEAS for ezetimibe. Int J Clin Pract 2008;62:1470-3
   PubMed Web of Science ®Google Scholar
• Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid lowering therapy in hypercholesterolemic postmenopausal women. Endorsed lipid lowering with EBT scanning. Circulation 2005;112:563-71
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361(9364). 1149-58
   PubMed Web of Science ®Google Scholar
• Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate risk individuals. JAMA 2012;308(8):788-95
   PubMed Web of Science ®Google Scholar
• Meade TW. Thrombosis and cardiovascular disease. Ann Epidemiol 1992;2:353-64
   Google Scholar
• Tracy RP. Inflammation in cardiovascular disease. Circulation 1998;97:2000-2
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-26
   PubMed Web of Science ®Google Scholar
• Hijmering ML, Stroes ESG, Pasterkamp G, et al. Variability of flow mediated dilation: consequences of clinical application. Atherosclerosis 2001;157:369-73
   PubMed Web of Science ®Google Scholar
• Fayad ZA, Mani V, Woodward M, et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378(9802):1547-59
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I, et al. ASTERIOD investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006;295:1556-65
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL investigators. JAMA 2004;291:1071-80
   PubMed Web of Science ®Google Scholar